Drugs / Octocrylene

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) ANTHELIOS SX 2006-07-21 fda.gov

Trials 3 · a red edge is where a trial was stopped

2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT05736224 May → Sep 2023 skin cancer Yale University Completed No outcome recorded
Phase 1 NCT03582215 Jul 2018 → Feb 2019 skin sensitivity to sun Food and Drug Administration (FDA) Completed No outcome recorded
Phase not applicable1 trial
NCT00530387 Jul 2008 → Jul 2011 photoallergic dermatitis NHS Tayside Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Octocrylene “The sunscreen contains bioadhesive nanoparticles (BNP) encapsulating avobenzone and octocrylene plus the non-toxic natural products diosmin, ferulic acid, cytisine and...” NCT05736224
2

“Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule” NCT03582215

OctocryleneNCT00530387

Known as NSC-760433 ChEMBL registry synonym — accepted as the source's own label CHEMBL1201147
Known as Octocrilene ChEMBL registry synonym — accepted as the source's own label CHEMBL1201147
Known as Octocrileno ChEMBL registry synonym — accepted as the source's own label CHEMBL1201147
Known as Octocrylene component of anthelios sx ChEMBL registry synonym — accepted as the source's own label CHEMBL1201147
Known as Octocrylene component of capital soleil ChEMBL registry synonym — accepted as the source's own label CHEMBL1201147
Modality Small molecule CHEMBL1201147